SciSparc Welcomes Professor Nir Peled to Advisory Board
![SciSparc Welcomes Professor Nir Peled to Advisory Board](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
SciSparc Welcomes Professor Nir Peled to Advisory Board
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company, has made significant strides in its mission to develop therapies for central nervous system disorders. In a recent announcement, SciSparc revealed that MitoCareX Bio Ltd., its collaborative venture with Dr. Alon Silberman, has appointed Professor Nir Peled to its Scientific Advisory Board.
Expertise of Professor Nir Peled
Professor Nir Peled, a highly regarded oncologist, currently serves as the Director of the Oncology Department at Shaare Zedek Medical Center in Jerusalem. He holds numerous board certifications, including internal medicine, pulmonology, and medical oncology. His extensive expertise has made him a prominent figure in the field of thoracic oncology.
Contributions to the Field
His contributions to lung cancer research and treatment are extensive. Professor Peled has served as a board member of the International Association for the Study of Lung Cancer (IASLC) and has held key roles such as the Chair of the Global Multidisciplinary Practice Standards Committee. Moreover, he has recently concluded his term as Chair of the Thoracic Cancer Assembly of the European Thoracic Society.
Professor Peled’s research primarily focuses on personalized targeted therapy, immunotherapy, cancer evolution, and biomarker development, allowing for early detection of lung cancer. He has authored over 250 peer-reviewed publications that highlight crucial guidelines on early diagnosis, biomarker development, and advanced disease treatment.
Innovation at MitoCareX
Dr. Alon Silberman, CEO of MitoCareX, expressed pride in welcoming Professor Peled, believing his contributions will be vital in propelling the company's innovative technologies for cancer treatment. MitoCareX engages in the drug discovery and development targeted towards life-threatening conditions by focusing on the mitochondrial SLC25 protein family.
Targeting Lung Cancer
The recent validation of the SLC25 carrier protein's involvement in Non-Small Cell Lung Cancer (NSCLC) marked a significant milestone for MitoCareX. The research demonstrated using genetic manipulations and 3D spheroid systems that mimic human tumors.
MitoCareX is leveraging a sophisticated computational platform, including its proprietary MITOLINE™ algorithm, to screen millions of small molecules. This virtual screening initiative has led to the identification of multiple potential anti-cancer treatments, expanding the company's pipeline of therapies.
About SciSparc Ltd.
SciSparc Ltd. is driven by an experienced team dedicated to advancing cannabinoid pharmaceutical technologies. The company's focus on innovative drug development includes programs like SCI-110, targeting Tourette Syndrome, agitation in Alzheimer’s disease, SCI-160 for pain management, and SCI-210 for ASD and status epilepticus treatment.
Future Directions
As SciSparc continues its commitment to research and development, the company remains proactive in enhancing its portfolio while exploring the therapeutic potential of cannabinoid medications. With a controlling interest in a subsidiary that focuses on hemp seed oil products sold on Amazon Marketplace, SciSparc is positioned for strategic growth in diverse health markets.
Frequently Asked Questions
Who is Professor Nir Peled?
Professor Nir Peled is a renowned oncologist appointed to the Scientific Advisory Board of MitoCareX, contributing his expertise in thoracic oncology.
What is MitoCareX?
MitoCareX is a venture of SciSparc focusing on drug discovery and development targeting mitochondrial SLC25 proteins for cancer therapies.
What role will Professor Peled play at MitoCareX?
He will provide valuable insights and guidance in advancing the company's innovative cancer treatment technologies.
What are SciSparc's main drug development focus areas?
SciSparc's current focus includes cannabinoid-based treatments for disorders such as Tourette Syndrome, Alzheimer's, pain management, and autism spectrum disorder.
How is MitoCareX advancing cancer therapy?
MitoCareX utilizes advanced computational drug discovery methods and validation studies to identify promising small molecules for cancer treatment.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Projected Growth of the Software Market to USD 2.25 Trillion
- Vow ASA Invites Shareholders to H1 2024 Results Presentation
- AEG and Onex Partners Complete Sale of ASM Global to Legends
- Dr. Brittany Mitchell Joins Washington Gastroenterology Team
- SkyQuest Projects Rapid Growth in Intelligent Process Automation
- Rotator Cuff Injury Treatment Market Growth and Trends
- High-Performance Computing Market Growth to USD 92.33 Billion
- Firefighting Drone Market Expected Growth to USD 3.5 Billion
- Crystal Oscillator Market Growth to USD 4.7 Billion Insights
- IVF Service Market Expected to Reach USD 4838.7 Million